Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (IBRX +35.56%), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible slate of good news. This morning, the company announced two bits of great news. First, enrollment for the company's Anktiva therapy exceeded expectations in a trial when treating non-muscle-invasive bladder cancer. This development means ImmunityBio could submit a biologics licensing agreement to the FDA by year's end.
Second, another clinical trial showed that the company's CAR-NK therapy demonstrated 100% disease control in its first four patients with Non-Hodgkin lymphoma. This update could have significant, longer-term implications for ImmunityBio as it develops next-gen therapies beyond its first hit, Anktiva.
NASDAQ: IBRX
Key Data Points
ImmunityBio's incredible week
These fantastic updates occur just:
- one day after management announced preliminary 2025 financials, where Anktiva sales grew over 700%, easily beating Wall Street's expectations
- two days after the Saudi Food and Drug Authority approved Anktiva for use in the country
- three days after the company released positive data on Anktiva treating non-small cell lung cancer
- one week after Anktiva came one step closer to receiving marketing approval across the E.U. from the European Commission
Image source: Getty Images.
The market greeted these six news items with jubilation, as it took a more optimistic view of Anktiva's growing sales, its potentially expanding indications, and ImmunityBio's initial success with longer-term, next-gen therapies. While it is challenging to assign a valuation to ImmunityBio's operations, as it only started generating revenue in 2024, its $5.3 billion market capitalization isn't outrageous given the success it has seen in the last week alone. Armed with roughly $800 million in net cash, ImmunityBio is a well-funded immunotherapy growth stock to watch -- but it could be a volatile ride.
